Eli Lilly and CoFRA:LLY0 +6.45%98 OCF Margin % is 26.94% as of Mar. 2026, which is 5% above its 10-year median of 25.75. GuruFocus rates FRA:LLY0 with a GF Score™ of 98/100 and a GF Value™ of €30.80 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 959 Drug Manufacturers companies, Eli Lilly and Co ranks better than 91.24% on this metric.
The historical rank and industry rank for Eli Lilly and Co's OCF Margin % or its related term are showing as below:
FRA:LLY0'
s OCF Margin % Range Over the Past 10 Years
Min: 12.43 Med: 25.75 Max: 28.11
Current: 28.3
During the past 13 years, the highest OCF Margin % of Eli Lilly and Co was 28.11%. The lowest was 12.43%. And the median was 25.75%.
FRA:LLY0's OCF Margin % is ranked better than 91.24% of 959
companies
in the Drug Manufacturers industry
Industry Median: 9.94
vs FRA:LLY0: 28.30
Eli Lilly and Co OCF Margin % Related Terms
Eli Lilly and Co OCF Margin % Historical Data
* Premium members only.
The historical data trend for Eli Lilly and Co's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:LLY0 vs JNJ, ABBV, MRK: OCF Margin % Comparison
For the Drug Manufacturers - General subindustry, Eli Lilly and Co's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eli Lilly and Co OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Eli Lilly and Co's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eli Lilly and Co (FRA:LLY0) has a OCF Margin % of 26.94% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Eli Lilly and Co and its competitors. This is near median its historical median of 25.75. Over the past decade, Eli Lilly and Co's OCF Margin % has ranged from 12.43 to 28.11. According to the industry distribution chart, Eli Lilly and Co ranks #84 out of 959 companies in the Drug Manufacturers industry, placing it in the top 8.8%.
Is Eli Lilly and Co's OCF Margin % too high?
Eli Lilly and Co's current OCF Margin % of 26.94% is near median its 10-year median of 25.75. Over the past 10 years, this metric has ranged from a low of 12.43 to a high of 28.11. The Drug Manufacturers industry median OCF Margin % is 9.94. Eli Lilly and Co's value of 26.94% is 171% above this industry median. Based on the distribution chart, Eli Lilly and Co ranks #84 out of 959 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Eli Lilly and Co has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's OCF Margin % compare to JNJ and ABBV?
According to the Drug Manufacturers industry distribution chart, Eli Lilly and Co ranks #84 out of 959 companies for OCF Margin %. This places Eli Lilly and Co in the top 9% of its industry — outperforming the majority of peers. The industry median OCF Margin % is 9.94. Eli Lilly and Co's value of 26.94% is 171% above this benchmark. Historically, Eli Lilly and Co's own OCF Margin % has ranged from 12.43 to 28.11 over the past decade. While the company's 10-year median is 25.75 vs. the industry median of 9.94, Eli Lilly and Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 9.94, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eli Lilly and Co's current OCF Margin % of 26.94% is 171% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Eli Lilly and Co and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 9.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eli Lilly and Co's current OCF Margin % is 26.94%, which is near median its own 10-year median of 25.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Based on GuruFocus' analysis, Eli Lilly and Co (FRA:LLY0) is currently considered Modestly Undervalued. The stock's GF Value™ is €30.80, compared to a current price of €26.40 — trading 14.3% below its estimated fair value. The current OCF Margin % is 26.94%, which is near median its 10-year median of 25.75 and 171% above the Drug Manufacturers industry median of 9.94. Eli Lilly and Co's overall GF Score™ is 98/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Eli Lilly and Co (FRA:LLY0), the current OCF Margin % is 26.94% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eli Lilly and Co (FRA:LLY0) Overvalued in 2026?
Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued.
The current stock price of €26.40 is trading 14.3% below its estimated GF Value™ of €30.80.
GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.
Key valuation signals for FRA:LLY0:
OCF Margin %: 26.94% (near median its 10-year median of 25.75)
GF Value™: €30.80 vs. price of €26.40 (14.3% below fair value)
Industry Position: 171% above the Drug Manufacturers median (#84 of 959)
No single metric tells the full story. See the FRA:LLY0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
98GF Score
Get the complete analysis for FRA:LLY0
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LLY0 has been successfully added to your 
